Financial Information

This section of the Co-Diagnostics InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing. 

Please note:  All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes.  Co-Diagnosticsassumes no responsibility for the accuracy of this data and provides it for informational purposes only.

NASDAQCODX
Beta(1.82)
Shares Outstanding28.3M
Average Volume (10 days)1.6M
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)$0.90
Sales (TTM)$1.68
Book Value (MRQ)$1.87
Cash Flow (TTM)$0.27
Cash (MRQ)$0.97

Analyst Views

Current Mean RecommendationStrong Buy
Strong Buy2
 
Buy0
 
Hold0
 
Underperform0
 
Sell0
 

Recent Insider Transactions

Dwight H Egan
Director, Chief Executive Officer
(11,954)
Dispose
Jan 15, 2021
Dwight H Egan
Director, Chief Executive Officer
(38,046)
Sell
Jan 15, 2021
Richard S. Serbin
Director
(10,000)
Sell
Jan 14, 2021
James Nelson
Director
(11,900)
Sell
Jan 13, 2021
James Nelson
Director
(600)
Sell
Jan 13, 2021

Recent SEC Filings

Insider Buy/Sell
Feb 25, 2021
New Insider
Feb 25, 2021
Company Events
Feb 22, 2021
>= 5% Acquisition
Feb 10, 2021
>= 5% Acquisition
Feb 2, 2021

Co-Diagnostics, Inc.
2401 South Foothill Dr, Suite D
Salt Lake City, Utah 84109
United States

1 (801) 438-1036

info@codiagnostics.com

© 2016-2020 Co-Diagnostics, Inc. • All Rights Reserved.

LATEST NEWS RELEASE

Co-Diagnostics is a molecular diagnostics company with a unique mathematical approach to DNA test design. Our products offer a unique value proposition, making the detection of infectious disease and genetic disorders far more affordable worldwide.

Click here to learn more

Co-Diagnostics, Inc.
2401 South Foothill Dr, Suite D
Salt Lake City, Utah 84109
United States

1 (801) 438-1036

info@codiagnostics.com

COMPANY

 

© 2016-2020 Co-Diagnostics, Inc. • All Rights Reserved.